DASH Trial
Start date:June 2019
Why?
Medications to ‘thin’ the blood can have an unwanted effect on strokes caused by bleeding in the brain. Controlling bleeding is crucial in the first few hours after stroke but there is still uncertainty over the best course of treatment.
What?
DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.
Research Team
Allan MacRaild
Stroke Lead Research Nurse
Seona Burgess
Senior Stroke Research Nurse
Pat Taylor
Senior Stroke Research Nurse
Rachel O'Brien
Lead Research Nurse
Julia Grahamslaw
Lead Research Nurse
Fiona McCurrach
Senior Research Nurse
More EMERGE Trials
To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.
PRECISE-CTCA Trial
To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.